BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30113434)

  • 1. Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.
    Hendifar AE; Delpassand ES; Kittleson MM; Tuli R
    Pancreas; 2018 Sep; 47(8):e55-e56. PubMed ID: 30113434
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with
    Estorch M
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):69-71. PubMed ID: 28257748
    [No Abstract]   [Full Text] [Related]  

  • 3. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
    Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Miederer M; Schreckenberger M; Krause BJ; Bengel FM; Bartenstein P; Biersack HJ; Pöpperl G; Baum RP
    Eur J Cancer; 2016 May; 58():41-51. PubMed ID: 26943056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event.
    Karfis I; Marin G; Machiels G; Hendlisz A; Flamen P
    Clin Nucl Med; 2018 Jul; 43(7):e232-e233. PubMed ID: 29762236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
    Kaewput C; Vinjamuri S
    Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
    Bodei L; Modlin IM; Luster M; Forrer F; Cremonesi M; Hicks RJ; Ezziddin S; Kidd M; Chiti A
    Endocr Relat Cancer; 2016 Aug; 23(8):C1-7. PubMed ID: 27353035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 90Y/177Lu-DOTATATE therapy: survival of the fittest?
    Brans B; Mottaghy FM; Kessels A
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1785-7. PubMed ID: 21755369
    [No Abstract]   [Full Text] [Related]  

  • 14. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
    Kesavan M; Turner JH
    Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radionuclide Therapy for Neuroendocrine Tumors.
    Cives M; Strosberg J
    Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polish experience in Peptide receptor radionuclide therapy.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
    Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
    Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRRT as neoadjuvant treatment in NET.
    Sowa-Staszczak A; Hubalewska-Dydejczyk A; Tomaszuk M
    Recent Results Cancer Res; 2013; 194():479-85. PubMed ID: 22918777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
    Kwekkeboom DJ; Krenning EP
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.